Ian A Rowe
Affiliation: University of Birmingham
- Assessment of the quality of evidence underlying international guidelines in liver diseaseIan A Rowe
Centre for Liver Research and National Institute for Health Research Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK
Am J Gastroenterol 107:1276-82. 2012..We aimed to describe the overall quality of evidence supporting international guidelines in liver disease...
- Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefitI A Rowe
Hepatitis C Virus Research Group, University of Birmingham, UK
Aliment Pharmacol Ther 36:670-9. 2012..There is however uncertainty regarding how, and in whom, these agents should be used. In previously treated subjects, prior response to interferon has a major effect on SVR rates with protease inhibitor therapy...
- Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementationIan A Rowe
Hepatitis C Virus Research Group, University of Birmingham, Birmingham, United Kingdom
Hepatology 56:501-6. 2012..The NNV to prevent one death per year is therefore 814,849, assuming 90% vaccine uptake and 94.3% vaccine efficiency. The vaccine cost for this totals $162 million, or $80.1 million per death prevented per year...
- Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?Ian A Rowe
Liver and Hepatobiliary Unit, University Hospital Birmingham NHS Trust, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK
World J Gastroenterol 16:5070-6. 2010..To investigate the outcome of patients with hepatitis C virus (HCV) infection undergoing liver retransplantation...
- Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?Diarmaid D Houlihan
Centre for Liver Research, National Institute for Health Research, University of Birmingham, Birmingham, United Kingdom
Liver Transpl 17:1292-8. 2011..Renal-sparing immunosuppression regimens should be considered at the time of LT to reduce the development of kidney injury in NASH patients. The optimization of such regimens requires a prospective study...
- A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migrationGarrick K Wilson
Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
J Hepatol 56:803-9. 2012..However, the role of infection in HCC pathogenesis is poorly understood. We investigated the effect(s) of HCV infection and viral glycoprotein expression on hepatoma biology to gain insights into the development of HCV associated HCC...
- Hepatitis C virus infects the endothelial cells of the blood-brain barrierNicola F Fletcher
Hepatitis C Research Group, Institute for Biomedical Research, University of Birmingham, Birmingham, England
Gastroenterology 142:634-643.e6. 2012..However, it is unclear whether such cognitive abnormalities are a function of systemic disease, impaired hepatic function, or virus infection of the CNS...
- A comparative quality assessment of evidence-based clinical guidelines in endocrinologyJonathan M Hazlehurst
The Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
Clin Endocrinol (Oxf) 78:183-90. 2013..There has been an expansion in guideline production although some of the heterogeneous methods used to assess the quality of the underlying evidence base might limit interpretation and implementation...
- The impact of disease recurrence on graft survival following liver transplantation: a single centre experienceIan A Rowe
Liver Unit, Queen Elizabeth Hospital, Birmingham, UK
Transpl Int 21:459-65. 2008..Disease recurrence is a significant cause of graft loss particularly in HCV, PSC and AIH. Recurrent disease, in part, explains the increased overall risk of graft loss in these groups...